QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
OTCMKTS:GNMSF

Genmab A/S (GNMSF) Stock Forecast, Price & News

$363.01
-11.46 (-3.06%)
(As of 09/21/2023 ET)
Compare
Today's Range
$363.01
$369.80
50-Day Range
$357.70
$421.26
52-Week Range
$303.41
$470.50
Volume
102 shs
Average Volume
330 shs
Market Capitalization
N/A
P/E Ratio
36.23
Dividend Yield
N/A
Price Target
N/A

GNMSF stock logo

About Genmab A/S (OTCMKTS:GNMSF) Stock

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

GNMSF Price History

GNMSF Stock News Headlines

Short Interest in Genmab A/S (OTCMKTS:GNMSF) Expands By 6.3%
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Genmab Updates 2023 Financial Guidance
Expert Ratings for Genmab
Analyst Ratings for Genmab
P/E Ratio Insights for Genmab
This Foreboding Sign Looms Over Genmab's Chart
GNMSF Genmab A/S
See More Headlines
Receive GNMSF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

GNMSF Company Calendar

Last Earnings
8/03/2023
Today
9/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:GNMSF
Employees
1,660
Year Founded
1999

Profitability

Net Income
$781.91 million
Pretax Margin
36.62%

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$12.86 per share
Book Value
$59.44 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.89

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Jan G.J. van de Winkel Ph.D. (Age 62)
    Co-Founder, Pres & CEO
    Comp: $2.7M
  • Mr. Anthony Pagano (Age 45)
    Exec. VP & CFO
    Comp: $1.01M
  • Mr. Anthony Mancini (Age 52)
    Exec. VP & COO
    Comp: $1.09M
  • Mr. Martin Schultz (Age 47)
    Sr. Director of Clinical Operations & Non-Independent Director
    Comp: $71.93k
  • Dr. Judith V. Klimovsky M.D. (Age 65)
    Exec. VP & Chief Devel. Officer
    Comp: $1.14M
  • Dr. Tahamtan Ahmadi (Age 50)
    Exec. VP, Chief Medical Officer & Head of Experimental Medicines
    Comp: $1.08M
  • Dr. Mijke Zachariasse Ph.D. (Age 49)
    Sr. Director, Head of Antibody Research Materials & Non-Independent Director
    Comp: $143.86k
  • Mr. Takahiro Hamatani (Age 48)
    Sr. Director of Fin. Japan & Non-Independent Director
    Comp: $71.93k
  • Mr. Andrew Carlsen
    Sr. Director, VP & Head of Investor Relations
  • Ms. Birgitte Stephensen M.Sc. (Age 62)
    Exec. VP & Chief Legal Officer













GNMSF Stock - Frequently Asked Questions

How have GNMSF shares performed in 2023?

Genmab A/S's stock was trading at $427.50 at the beginning of the year. Since then, GNMSF shares have decreased by 12.4% and is now trading at $374.47.
View the best growth stocks for 2023 here
.

Are investors shorting Genmab A/S?

Genmab A/S saw a increase in short interest in August. As of August 31st, there was short interest totaling 11,800 shares, an increase of 6.3% from the August 15th total of 11,100 shares. Based on an average trading volume of 800 shares, the short-interest ratio is presently 14.8 days.
View Genmab A/S's Short Interest
.

How were Genmab A/S's earnings last quarter?

Genmab A/S (OTCMKTS:GNMSF) released its quarterly earnings data on Thursday, August, 3rd. The company reported $3.01 EPS for the quarter. The business earned $613.43 million during the quarter. Genmab A/S had a trailing twelve-month return on equity of 16.93% and a net margin of 28.78%.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the OTCMKTS under the ticker symbol "GNMSF."

How do I buy shares of Genmab A/S?

Shares of GNMSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GNMSF stock can currently be purchased for approximately $374.47.

How many employees does Genmab A/S have?

The company employs 1,660 workers across the globe.

How can I contact Genmab A/S?

Genmab A/S's mailing address is KALVEBOD BRYGGE 43, COPENHAGEN G7, 1560. The official website for the company is www.genmab.com. The company can be reached via phone at (457) 020-2728, via email at acn@genmab.com, or via fax at 45-7020-2729.

This page (OTCMKTS:GNMSF) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -